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A B S T R A C T
Herein we report the in-vivo characterisation and metabolic changes in Galleria mellonella larvae to a series of bis-
chelate copper(II) phenanthroline-phenazine cationic complexes of [Cu(phen)2]2+ (Cu-Phen), [Cu(DPQ)
(Phen)]2+ (Cu-DPQ-Phen) and [Cu(DPPZ)(Phen)]2+ (Cu-DPPZ-Phen) (where phen= 1,10-phenanthroline,
DPQ=dipyrido[3,2-ƒ:2′,3′-h]quinoxaline and DPPZ=dipyrido[3,2-a:2′,3′-c]phenazine). Our aim was to in-
vestigate the influence of the systematic extension of the ligated phenazine ligand in the G. mellonella model as a
first step towards assessing the in-vivo tolerance and mode of action of the complex series with respect to the
well-studied oxidative chemical nuclease, Cu-Phen. The Lethal Dose50 (LD50) values were established over dose
ranges of 2 – 30 μg at 4-, 24-, 48- and 72 h by mortality assessment, with Cu-Phen eliciting the highest mortality
at 4 h (Cu-Phen, 12.62 μg < Cu-DPQ-Phen, 21.53 μg < Cu-DPPZ-Phen, 26.07 μg). At other timepoints, a si-
milar profile was observed as the phenazine π-backbone within the complex scaffold was extended. Assessment
of both cellular response and related gene expression demonstrated that the complexes did not initiate an im-
mune response. However, Label-Free Quantification proteomic data indicated the larval response was associated
with upregulation of key proteins such as Glutathione S-transferase, purine synthesis and glycolysis/gluconeo-
genesis (e.g. fructose-bisphosphate aldolase and glyceraldehyde-3-phosphate). Both Cu-Phen and Cu-DPQ-Phen
elicited a similar in-vivo response in contrast to Cu-DPPZ-Phen, which displayed a substantial increase in ni-
trogen detoxification proteins and proteins with calcium binding sites. Overall, the response of G. mellonella
larvae exposure to the complex series is dominated by detoxification and metabolic proteome response me-
chanisms.
1. Introduction
Almost 40 years since receiving Federal Drug Administration (FDA)
approval, cisplatin still remains one of the most important che-
motherapies available today for the combination treatment of cancers
including metastatic testicular and ovarian cancers, bladder and lung.
However, dose limiting side effects including neurotoxicity and ne-
phrotoxicity and the development of both acquired and inherently re-
sistant cancers continue to be an ongoing issue in its treatment success.
As such, recent research activity has focused on the rational design of
metallo-agents including ruthenium [1–5], iron [6, 7], gold [8–10] and
copper [11–19] with alternative mode of action to the mono-nuclear
cis-[PtX2(amine)2] chemotype (X= leaving group, amine=neutral or
carrier group) shared by cisplatin and its derivatives [20].
Copper is an endogenous metal ion that plays an essential role in the
structure and activity of multiple functional protein classes, such as
enzymes designated to detoxification and oxidative phosphorylation.
The essential nature of copper in the cell and its complex homeostasis
through specific transporters and trafficking proteins; Copper
Transporter 1/2 (CRT1 and CRT2), ATPase copper transporting 7
alpha/beta (ATP7α and ATP7β) holds a strong potential for the utili-
sation of copper as part of a metallodrug [21].
The therapeutic development of copper complexes has progressed to
an advanced stage with two members of the Reactive Oxygen Species
(ROS)-active, mixed chelate Casiopeinas® class recently entering phase
I clinical trials [22]. The compounds have previously shown anti-
proliferative and antitumoural effects in medulloblastoma [23], glioma
[24] and colorectal adenocarcinoma [25] cell lines. Their mechanism of
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action is not fully understood, however they are believed to exert their
biological effects through (i) binding Deoxyribonucleic Acid (DNA)
with intercalative and non-intercalative methods at high affinities, (ii)
degrading nucleic acids through the generation of ROS and depleting
the antioxidant systems, and (iii) inducing mitochondrial toxicity [26].
Further examples of ternary mixed ligand chelated copper (II) com-
plexes include a developmental therapeutic [Cu(o-phthalate)(1,10-
phenanthroline)]2+ encorporating a bis-chelate dicarboxylate and
N,N′-intercalative square planar coordination scaffold that has recently
shown endogenous ROS production inducing DNA damage and mi-
tochondrial depolarisation resulting in apoptotic induction [16]. Fur-
thermore, the cytotoxic profile of the complex within the National
Cancer Institute (NCI) Developmental Therapeutics Program (DTP) 60
human cancer cell panel revealed a novel mode of action to existing
metal-based therapeutics.
At the heart of the promising chemotherapeutic potential exerted by
many copper(II) complexes lies the artificial metallo-nuclease activity
of the parent copper(II) bis-1,10-phenanthroline (Cu-Phen) agent [27].
Evidence suggests the complex binds DNA predominately in the minor
groove and in its reduced form abstracts a hydrogen atom primarily
from the C1′ deoxyribose position resulting in strand damage [28, 29],
with di‑copper chemotypes demonstrating singlet oxygen and super-
oxide production [30]. However, the nuclease binds both nucleic acids
and proteins without specificity inducing general toxicity, and is thus
considered a “promiscuous” agent [31]. Accordingly, manipulation of
this chemotype represents an interesting developmental challenge.
With this in mind, a range of novel Cu(II) chemical nucleases of [Cu
(phen)(N,N′)]2+ carrying designer phenazine type-intercalators (where
N,N′ represents phen=1,10-phenanthroline, DPQ=dipyrido[3,2-
ƒ:2′,3′-h]quinoxaline and DPPZ=dipyrido[3,2-a:2′,3′-c]phenazine)
were developed by Molphy et al. to identify how the systematic ex-
tension of the ligated phenanthrene ligand influences nucleotide
binding affinity, base selectivity, oxidative chemical nuclease activity,
and cytotoxicity within human cancer cells [32]. Agents within this
series showed potent intercalative selectivity, high-affinity duplex-DNA
binding constants and significant in-vitro cytotoxicity in the SKOV3
cisplatin-resistant ovarian cell line.
Galleria mellonella larvae have become an important model for
studying human pathogens in addition to being an evaluative me-
chanism for antimicrobial and antifungal testing [33–36]. A number of
factors contribute to this Lepidoptera species being a viable screening
model such as: the possession of a similar humoral and cellular immune
response to mammals [35, 37], the ability to incubate pathogens at
human physiological temperature [34], the physical size of the larvae
allowing for ease of inoculation and visual effects being readily ob-
servable [38], and having lower ethical and financial restrictions
associated with their use [39]. Haemocyte-mediated ROS production
has been proposed to be central to the immune response of G. mellonella
[40]. Several genes have been found to be up regulated during infection
and provide a good indicator of the immunogenic nature of the insult
on the larvae [41]. Several studies examining toxicities and assessing
larval tolerance have been undertaken against a range of metal com-
plexes. The cytotoxicity and subsequent biological activity of Cu(II) 1,
10-phenanthroline and Cu(II) 1, 10-phenanthroline-5,6-dione was well
tolerated by the larvae in addition to showing strong in-vitro activity in
mammalian cells lines [42]. A further study involving a series of Imi-
dazole Schiff base ligands complexed to Ag(I), Cu(II) and Zn(II) were
shown to be well tolerated in G. mellonella larvae [43]. A subsequent
study showed the tolerance of larvae to Ag(I) carbine complex provided
an opportunity to assess the antimicrobial activity which showed in-
creased survival following infection with Candida albicans [44]. G.
mellonella larvae have also demonstrated a high degree of tolerance to
both Cu2+ 1, 10-phenanthroline octanedionate and Mn2+ 1, 10-phe-
nanthroline octanedionate complexes [45]. A mechanistic study of this
nature would help provide key insights into the activity and potential
molecular targets of Cu(II) phenanthroline-phenazine complexes in an
in-vivo context and aid in future biological testing.
Given the promising activity of Cu(II) phenanthroline-phenazine
complexes, [32, 46] the current study seeks to characterise the in-vivo
toxicity, immune related gene expression and proteomic effects of Cu-
Phen, Cu-DPQ-Phen and Cu-DPPZ-Phen in G. mellonella larvae. Pro-
teomic responses were recorded through Label Free Quantification
(LFQ) in addition to 2-Dimensional Polyacrylamide gel electrophoresis
(2D PAGE) methods. LFQ allows a high-resolution assessment of the
proteomic changes in the larvae and is becoming an increasingly im-
portant tool in identifying the mode of action in in-vitromammalian cell
models [47, 48]. Owing to the similarity between the larval and
mammal system, this approach will provide valuable insights into the
potential mode of action of the phenazine-functionalised Cu(II) phe-
nanthroline complexes in mammalian models.
2. Materials and methods
2.1. Preparation of Cu(II) complexes
Cu-Phen (1), Cu-DPQ-Phen (2) and Cu-DPPZ-Phen (3) (Fig. 1) were
synthesised and characterised as previously described [32]. Complexes
were initially dissolved in Dimethyl Sulfoxide (DMSO) (Sigma, Ireland)
followed by dilution in working aqueous solution. Individual doses
were made up in sterile water from the stock solution producing a range
between 1500 and 200 μg cm−3.
Abbreviations
2D PAGE 2 dimensional poly acrylamide gel electrophoresis
AICAR transformylase-phosphoribosylaminoimidazolecarbox-
amide formyltransferase
ATP7A/B ATPase copper transporting alpha/beta
CTR1/2 Copper Transporter 1/2
DMSO Dimethyl Sulfoxide
DNA Deoxyribonucleic Acid
DTT Dithiothreitol
FDA Federal Drug Administration
FDR false discovery rate
GO Gene Ontology
GST Glutathione S-transferase
HSP Heat Shock Protein
IAA Iodoacetamide
IMPI Inducible of Metalloproteinase Inhibitor
KEGG Kyoto Encyclopedia of Genes and Genomes
LD50 Lethal Dose (50%)
LFQ Label Free Quantitative (proteomics)
MDR Multi Drug Resistance
mRNA messenger Ribonucleic Acid
NAD Nicotinamide Adenine Dinucleotide
NCI DTP National Cancer Institute Developmental Therapeutics
Program
PCA principle component analysis
qRT-PCR quantitative Real-Time Polymerase Chain Reaction
ROS Reactive Oxygen Species
SAICAR synthase pho-
ocarboxamide synthase
SBC3 1,3-dibenzyl-4,5-diphenyl-imidazol-2-ylidene silver(I)
acetate
SOD Superoxide Dismutase
TCA Tricarboxylic Acid (cycle)
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2.2. Galleria mellonella mortality and haemocyte density assessment
Galleria mellonella larvae of the 6th instar development stage were
sourced from Livefoods Direct Ltd. (Sheffield, England) and were stored
in the dark at 15 °C in wood shavings prior to testing. Thirty three
larvae for each replicate (11× 3) (average weight 0.3 ± 0.05 g) with
no cuticle decolouration were used for each experimental condition. All
test solutions were prepared immediately prior to testing. Larvae were
inoculated with 20 μL of the test complex [49]. A solvent control
(8.94% DMSO) in Sterile MilliQ water was inoculated along with sham-
inoculations and undisturbed controls. Larval mortality was recorded
over 72 h after incubation at 30 °C. The lethal dose (LD) concentration
inducing 50% larval death (LD50) for each timepoint was calculated
using non-linear regression analysis (GraphPad Prism ver. 5.0). Hae-
mocyte density assessment was determined [50] after inoculation with
the 24 h LD50 exposures. The exposure was performed on 4 independent
occasions, utilising 5 larvae per exposure. Haemocyte density was re-
presented by mean ± standard deviation.
2.3. Induction of IMPI and transferrin by quantitative Real Time – PCR
(qRT-PCR)
Inducible metalloproteinase inhibitor (IMPI) and transferrin are com-
monly seen to be raised in insect based immune reactions [51, 52]. IMPI
and transferrin (Table 1) were therefore assessed for their expression re-
lative to the reference gene S7e (ribosomal subunit) after larvae were in-
oculated with the 24 h LD50 value of Cu-Phen (1), Cu-DPQ-Phen (2) and Cu-
DPPZ-Phen (3). Controls for the solvent, injection (sham-inoculation) and
temperature (undisturbed) were included in the assessment. Total RNA was
extracted from the larvae by snap freezing (liquid nitrogen) 3 larvae (re-
presentative of each condition) as previously described [53]. qRT-PCR was
performed on the 7500 Real-Time PCR system (Applied Biosystems®) using
SYBR FAST qPCR kit (KAPA Biosciences) (See S-1 for parameters).
2.4. Label free quantification (LFQ) - proteomics
Larvae were inoculated with the 24 h LD50 values of Cu-Phen (1)
(8.94 μg), Cu-DPQ-Phen (2) (11.47 μg), Cu-DPPZ-Phen (3) (25.05 μg)
and solvent control (8.94% DMSO in MilliQ grade water). Haemolymph
protein from 5 pooled (performed 4 independent times) larvae were
extracted and quantified using the Bradford method [55]. Samples were
normalized to 100 μg prior to reduction with dithiotreitol (DTT;
200mM), followed by alkylation with iodoacetamide (IAA; 1M) and
digested with sequence grade trypsin (Promega, Ireland) at a ratio of
1:40 trypsin to protein over night at 37 °C. Prior to C18 column clean-
up, samples were separated by 1 Dimensional (1D) gel electrophoresis
along with a size ladder and stained with coomassie blue to verify the
presence and quantity of proteins in the samples. Following verifica-
tion, samples were subjected to a clean-up procedure utilising C18
columns with spin filters (Medical Supply Company, Ireland). Peptide
mix was separated on a Dionex Ultimate 3000 (RSLC nano) chroma-
tography system with increasing gradient of acetonitrile on a Biobasic
C18 PicofritTM column (100mm length, 75mm ID), using a 60min
reverse phase gradient at a flow rate of 250 nLmin–1. High-resolution
Mass Spectrometry (MS) (300–2000 Da) was performed using the Q
Exactive (ThermoFisher, USA) to select the 15 most intense ions prior to
MS/MS Q. Protein spots identified in the 2-Dimensional Polyacrylamide
Gel Electrophoresis (2D PAGE) analysis (see S-1 for details) were ex-
cised and trypsin digested similarly to the method described. [56]
Proteins were identified through the Andromeda search engine [57]
in MaxQuant (ver. 1.2.2.5, http://maxquant.org/) to correlate the data
against a 6-frame translation of the expressed sequence tag contigs
identified from complementary DNA (cDNA) for G. mellonella [58]. First
search peptide tolerance of 20 ppm was followed by the second search
peptide tolerance of 4.5 ppm with cysteine carbamidomethylation as a
fixed modification, N-acetylation of protein and oxidation of methio-
nine as variable modification, and a maximum of 2 missed cleavage
sites allowed. False discovery rate (FDR) was set to 1% for both pep-
tides and proteins and FDR was estimated following searches against a
target decoy database. Peptides with a minimum length of seven amino
acids were considered for identification and proteins were only con-
sidered identified when more than one unique peptide for each protein
was observed.
2.5. Statistical analysis
Larval mortality was used to establish LD50 using non-linear re-
gression analysis (GraphPad Prism, ver. 5.0). Gene expression was as-
sessed through the use of relative expression to the reference gene S7e
and was technically replicated on four occasions. Analysis of critical
threshold values was performed as per Livak and Schmittgen relative
expression method [59]. LFQ proteomics was run on 4 separate occa-
sions with Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis
(SDS PAGE) used to check the integrity of samples prior to Liquid
Chromatography/Mass Spectrometry (LC/MS) injection. Statistical and
graphical analysis of the LFQ proteomics was performed using Perseus
Table 1
Sequence of primers for IMPI and transferrin.
Gene (primers) Oligonucleotides sequence (5΄-3΄) Fragment size (base pair (bp)) Reference Function (encodes)
S7e F
S7e R
ATGTGCCAATGCCCAGTTG
GTGGCTAGGCTTGGGAAGAAT
131 [54] Structural ribosomal protein
Transferrin F
Transferrin R
CCCGAAGATGAACGATCAC
CGAAAGGCCTAGAACGTTTG
535 [41] Iron transport and binding
IMPI F
IMPI R
ATTTGTAACGGTGGACACGA
CGCAAATTGGTATGCATGG
409 [41] Inhibits pathogen secreted enzymes
Fig. 1. Molecular structure of Cu(II) coordination complexes (1–3).
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v. 1.5.0.31. Log2 –transformation was performed on all LFQ intensities
that met the identification criteria with subsequent ANOVA of sig-
nificance and t-tests between the solvent control and the test complexes
exposures. The p-value of 0.05 was set with significance determined
using FDR correction (Benjamini-Hochberg). Proteins were only in-
cluded when they were present in at least 3 of 4 biological replicates.
Proteins which had LFQ intensity values of zero (indicating absence or
low abundance) were included in the study only when the protein was
absent in one group and present in at least three replicates of another
group. Imputation was used to correct for missing identifications in
samples based on Gaussian distribution using the lowest value for each
dataset, which was calculated as being 1.75 downshift from the mean
value and 0.25 width in the downshift for the standard deviation. The
Blast2GO suite (www.blast2GO.com) of software tools was used to as-
sign annotation, enzyme code, Kyoto Encyclopedia of Genes and Gen-
omes (KEGG) and Gene Ontology (GO) mapping. GO mapping for
biological processes and molecular functions was graphed at level 4
ontology.
3. Results
3.1. Larval mortality assay and haemocyte count
G. mellonella larvae were administered with Cu-Phen (1), Cu-DPQ-
Phen (2), Cu-DPPZ-Phen (3) and cisplatin with the level of toxicity
being assessed by the mean mortality (%) over 72 h (Supplementary
Table I and II). No mortality (data not shown) was recorded at any
timepoint after incubation of solvent (8.94% DMSO in MilliQ water),
sham inoculated and undisturbed controls. The results of the individual
larval responses to the inoculated doses and timepoints are detailed in
S-1. The LD50 values (Table 2) from Cu-Phen (1), Cu-DPQ-Phen (2) and
Cu-DPPZ-Phen (3) decrease over the increasing timepoints with Cu-
Phen (1) showing superior toxicity to both Cu-DPQ-Phen (2) and Cu-
DPPZ-Phen (3) at all timepoints. Haemocytes were numerated from the
haemolymph extracted from 5 larvae per treatment (LD50 value at 24 h)
with this procedure replicated 4 times (for statistical validity). No sig-
nificant changes (data not shown) were observed between any of the
controls and test complex exposures.
3.2. Induction of IMPI and transferrin assessed by qRT-PCR
Larvae were exposed to the 24 h LD50 value of Cu-Phen (1), Cu-
DPQ-Phen (2) and Cu-DPPZ-Phen (3). Solvent control, sham-inocula-
tion and undisturbed control were utilised as previously described. Both
transferrin and IMPI were normalized against the expression of S7e
reference gene and all larval treatments were compared to the solvent
control. Both sham-inoculation and undisturbed controls produced si-
milar expression levels (data not shown). Fig. 2 demonstrates the ex-
pression of both genes. A significant decrease in IMPI expression
(Fig. 2) was observed in Cu-Phen (1), Cu-DPQ-Phen (2) and Cu-DPPZ-
Phen (3) treated larvae in comparison to the solvent control. In all LD50
complex exposures a significant decrease in transferrin activity (Fig. 2)
was observed with respect to the solvent control. The solvent control
demonstrated decreased expression in both measured genes in relation
to the undisturbed biological control.
3.3. Label free quantification (LFQ) – Proteomics between test exposures
and control
The haemolymph of larvae was extracted after the 24 h exposure to
the LD50 value of the complex series in order to assess the difference in
protein abundance between the treated and control larvae. A total of
299 proteins were detected with 2 or more peptides. One hundred and
four proteins were found to be significantly altered in abundance or
uniquely detected across the 4 conditions (Table 3). Nine proteins were
found to be absent or below the limit of detection following exposure to
Cu-DPQ-Phen (2). Twelve proteins were found to be absent or below
the detection limit following exposure to Cu-Phen (1). Four proteins
were found to be absent or below the limit of detection after exposure
to Cu-DPQ-Phen (2) and Cu-DPPZ-Phen (3). One protein was found to
be absent or below the limit of detection after exposure to Cu-Phen (1)
and Cu-DPPZ-Phen (3). Twenty-three proteins were found to be absent
or below the limit of detection after exposure to Cu-Phen (1) and Cu-
DPQ-Phen (2). Table 3 demonstrates increasing numbers of sig-
nificantly up regulated proteins in the following pattern: Cu-Phen
(1) < Cu-DPQ-Phen (2) < Cu-DPPZ-Phen (3). In the case of Cu-DPPZ-
Phen (3) exposure, a greater number of antimicrobial proteins were
observed to be significantly down regulated while a greater number of
metabolic proteins and proteins containing calcium binding sites were
up regulated. Principle component analysis (PCA) (Fig. 3) was used to
visualise the variation in protein abundance across the individual re-
plicates. The proteomes of larvae exposed to the solvent control and Cu-
DPPZ-Phen (3) showed clustering that was widely separated by com-
ponent 1 (greatest measure of profile divergence), however Cu-Phen (1)
and Cu-DPQ-Phen (2) were closely clustered, indicating a similar pro-
tein expression profile. Hierarchical clustering (Supplementary Fig. 2)
similarly reflected the PCA. Four replicates were included for the sol-
vent control and one replicate was removed from each of the test ex-
posures due to lack of clustering with the parent group. GO terms were
categorised by both biological processes (Fig. 4(A)) and molecular
Table 2
Calculated LD50 values. * Cu-DPPZ-Phen (3) injected in micro-suspension.
Compounds LD50 (μg) ± S.D
4 h 24 h 48 h 72 h
Cu-Phen (1) 12.62 ± 0.008 8.94 ± 0.006 8.94 ± 0.006 8.56 ± 0.75
Cu-DPQ-Phen (2) 21.53 ± 0.007 11.47 ± 0.006 10.69 ± 0.005 9.88 ± 0.017
Cu-DPPZ-Phen (3)* 26.07 ± 0.312 25.05 ± 0.312 25.05 ± 0.312 16.81 ± 0.236
Fig. 2. Relative expression of IMPI and transferrin after 24 h exposure to LD50
value of Cu-Phen (1), Cu-DPQ-Phen (2) and Cu-DPPZ-Phen (3). Gene expression
is displayed relative to the undisturbed control with the solvent control used to
determine significance (p < 0.05).
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function (Fig. 4(B)) with categorisations being performed at level 4
ontology. The biological process analysis (Fig. 4(A)) does not show any
major changes in larvae inoculated with the different complexes. Pro-
tein groups such as precursor metabolites, organonitrogen and cellular
nitrogen associated proteins were more prominent in terms of observed
proteins. An overall increase was observed in the number of proteins
recorded after exposure to Cu-DPQ-Phen (2) and Cu-DPPZ-Phen (3)
with the number of proteins increasing as the ligated phenazine π-
backbone was extended. However, the number of proteins associated
with each GO process proportionally increased in comparison to Cu-
Phen (1). Interestingly, proteins associated with sulphur compounds
and cellular aldehyde processes were only present after exposure to Cu-
Table 3
Statistically Significant Differentially Abundant (SSDA) proteins present in Cu-
Phen (1), Cu-DPQ-Phen (2) and Cu-DPPZ-Phen (3) in comparison to the solvent
control. Relative fold changes are given for each complex exposure in com-
parison to the solvent control.
Protein annotation Relative expression to solvent control
Cu-Phen
(1)
Cu-DPQ-
Phen (2)
Cu-DPPZ-
Phen (3)
Aldehyde dehydrogenase mitochondrial-
like
2.19 7.16 8.05
Selenium-binding 1 2.02 6.62 7.8
Lambda-crystallin homolog 4.89 6.76 7.55
Tubulin beta chain 4.64 6.37 7.41
D-arabinitol dehydrogenase 1-like 5.24 5.8 6.85
Elongation factor 1-alpha 6.19 5.57 6.63
15-hydroxyprostaglandin
dehydrogenase [NAD(+)]-like
2.96 5.05 6.49
Cytoplasmic A3a 1.28 5.74 6.4
N-acetylneuraminate lyase-like 5.17 5.69 6.38
Serine cytosolic isoform X1 0.63 5.48 6.36
Multifunctional ADE2 5.13 5.13 6.19
Cytosolic malate partial 2.81 4.97 6.16
D-3-phosphoglycerate dehydrogenase 3.05 5.27 6.04
Glutathione S-transferase-like 5.18 4.65 5.99
Tubulin alpha chain 4.68 4.6 5.9
Triosephosphate isomerase 4.92 4.96 5.87
Glutamine synthetase 2 cytoplasmic-like 3.61 5 5.41
Probable enoyl- mitochondrial 1.09 4.61 5.31
Glutathione S-transferase 1-1-like 2.78 4.6 5.22
Glyceraldehyde-3-phosphate partial 3.14 4.6 5.04
Fructose-bisphosphate aldolase isoform
X1
4.59 4.14 4.94
Superoxide dismutase [Mn]
mitochondrial
−1.52 3.53 4.7
Trans-1,2-dihydrobenzene-1,2-diol
dehydrogenase-like
4.69 4.17 4.7
Bifunctional purine biosynthesis PURH 1.75 3.7 4.56
Aminopeptidase 1.39 3.34 4.39
Heat shock 90 3.39 3.36 4.33
Enolase 3.49 2.95 4.32
L-threonine ammonia-lyase-like 4.08 3.3 4.27
Arginine partial 4.02 2.04 4.24
Aliphatic nitrilase 3.61 3.19 4.19
Dihydropteridine reductase 6.24 3.4 4.13
Peptidyl-prolyl cis-trans isomerase 3.03 3.12 4.13
Cholinesterase 1-like 6.1 3.64 4.02
Purine nucleoside phosphorylase 3.49 1.96 3.97
Cellular retinoic acid binding 5.01 3.06 3.77
Argininosuccinate synthase 1.28 2.66 3.74
Uncharacterized protein Dmoj_GI19595 2.25 1.91 3.65
Immune-related Hdd1 4.43 3.58 3.57
Ejaculatory bulb-specific 3-like 2.05 3.68 3.52
Fibrous sheath CABYR-binding 5.16 2.89 3.46
Leukotriene A-4 hydrolase isoform X2 2.13 3.26 3.13
PREDICTED: uncharacterized protein
LOC106129042
3.89 3.23 3.13
Ecdysteroid-regulated 16 kDa -like 2.54 3.23 2.64
Isopentenyl-diphosphate Delta-
isomerase 1
−1.01 2.13 2.55
Heat shock 1.98 2.2 2.4
Proliferation-associated 2G4 2.61 1.98 2.35
Seroin-like isoform X2 −2.06 1.37 2.28
Actin 1.63 4.22 1.99
Nucleoside diphosphate kinase −0.66 0.79 1.83
Chitin deacetylase 1 6.88 1.52 1.55
Contig19736_1_exp_NA 1.43 −1.62 −1.82
Homeobox 2-like isoform X4 3.15 −1.33 −2.15
Probable salivary secreted peptide 2.9 −1.72 −2.8
Gloverin-like 0.92 −2.5 −2.96
Peptidoglycan recognition 2.03 −4.02 −3.28
Glutathione S-transferase 1-like 5.11 – 4.67
Profilin 3.18 – 3.64
Aminoacrylate peracid reductase −0.69 – 3.35
Cytosolic non-specific dipeptidase 2.23 – 3.1
Circadian clock-controlled -like 3.01 – 2.7
4-Coumarate—ligase 1-like 1.16 – 2.62
Table 3 (continued)
Protein annotation Relative expression to solvent control
Cu-Phen
(1)
Cu-DPQ-
Phen (2)
Cu-DPPZ-
Phen (3)
Multiple inositol polyphosphate
phosphatase 1-like
1.14 – 1.86
Isocitrate partial 2.7 – 1.48
Esterase FE4-like 5.06 – −1.18
Thioredoxin – 3.87 4.81
Rab GDP dissociation inhibitor alpha – 3.15 4.55
Probable phosphoserine
aminotransferase
– 4.23 4.46
Small heat shock – 3.46 3.97
Takeout-like – 2.33 3.97
High mobility group D – 2.27 3.74
Staphylococcal nuclease domain-
containing 1
– 2.13 3.16
Glutathione S-transferase omega 1 – 2.07 2.92
Fumarylacetoacetase – 1.57 2.35
Hydroxypyruvate isomerase – 1.1 1.76
Apolipophorins isoform X2* – −4.15 −0.72
Chitinase EN03 (imaginal disc growth)* – −0.72 −1.5
Translationally controlled tumor 5.64 – –
Cysteine ase inhibitor precursor 2.71 – –
Gustatory receptor candidate 59 2.5 – –
Chemosensory 2.48 – –
Serpin-2 – 2.00 –
Muscle-specific 20 – – 5.73
Peroxiredoxin- mitochondrial – – 4.96
Tropomyosin-1 isoform X1 – – 4.22
Troponin T – – 4.18
Annexin B9 isoform X4 – – 4.15
Troponin I – – 3.97
Asteroid – – 3.62
Antichymotrypsin-2-like isoform X2 – – 3.56
Ubiquitin carboxyl-terminal hydrolase
isozyme L3
– – 3.14
S-Adenosyl-L-homocysteine partial – – 3.08
C-1-tetrahydrofolate cytoplasmic
isoform X2
– – 3.03
Troponin C – – 2.88
Phosphoglycerate mutase 1 – – 2.82
Probable transaldolase – – 2.78
ATPase inhibitor – – 2.28
Acyl-binding homolog – – 1.99
Proactivator polypeptide – – 1.74
Phosphotriesterase-related -like – – 1.71
L-threonine 3- mitochondrial – – 1.66
Prostaglandin reductase 1 – – 1.57
Vanin 2 isoform X1 – – −1.79
Chymotrypsin-like elastase family
member 2A
– – −2.3
Serine protease 42-like – – −2.41
- denotes level of expression that was either absent or not detected. Fold
changes of ˂1.5 were included when expression in other test exposures was
≥1.5 fold change. *Denotes protein also expressed in 2D PAGE analysis with a
similar profile, see Supplementary Table III. Numerical difference between the
detected proteins between the two proteomics methods was due to the greater
sensitivity of LFQ proteomics method.
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Fig. 3. Principle component analysis (PCA)
of haemolymph proteomic profiles of larvae
inoculated with Cu-Phen (1), Cu-DPQ-Phen
(2) and Cu-DPPZ-Phen (3) versus the solvent
control. PCA of four replicates for the sol-
vent control and three replicates for each of
the test exposures. Enclosures define the
different experimental conditions.
Component 1 on the x-axis represents the
largest difference in terms of protein ex-
pression profile with Component 2 on the y-
axis representing the next largest.
Fig. 4. Bar chart showing the different number of proteins present in a test exposure that is associated with selected biological processes (A) and molecular functions
(B). Comparative bar chart represents level 4 ontology.
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DPPZ-Phen (3). Analysis of molecular functions (Fig. 4(B)) also showed
a similar trend of increasing number of proteins involved in the func-
tionally categorised processes as the Cu(II) series progressed from Cu-
Phen > Cu-DPQ-Phen > Cu-DPPZ-Phen. Proteins associated with
coenzyme binding, oxidoreductases acting on CH-OH and peptidase
activity was only associated with exposure of Cu-Phen (1), while all
other protein groups were co expressed by all three test complexes.
Glutathione S-transferase (GST) highlighted in the KEGG analysis
(Fig. 5), exhibited an increased relative abundance following exposure
to Cu-Phen (1), Cu-DPQ-Phen (2) and Cu-DPPZ-Phen (3) in comparison
to the control. KEGG glycolysis/gluconeogenesis analysis (Fig. 6) of all
three complex exposures showed an upregulation of several proteins:
fructose bisphosphate, triose phosphate isomerase, glyceraldehydes-3-
phosphate dehydrogenase and phosphopyruvate hydratase (enolase).
KEGG analysis of purine metabolism (Fig. 7) showed increased relative
abundance of 6 proteins after exposure to all test complexes: phos-
phoribosylaminoimidazolesuccinocarboxamide (SAICAR) synthase,
phosphoribosylaminoimidazolecarboxamide (AICAR) for-
myltransferase, IMP cyclohydrolase, nucleoside-diphosphate kinase,
nucleoside-triphosphate phosphatise and purine-nucleoside phosphor-
ylase.
4. Discussion
The aim of this study was to assess the response of G. mellonella
larvae to novel copper phenanthroline-phenazine complexes as a means
to determine their biological mode of action and therefore develop-
mental potential. Larval mortality decreased as the ligated phenazine
ligand in the [Cu(phen)(N,N′)]2+ model was extended (Cu-Phen
(1) > Cu-DPQ-Phen (2) > Cu-DPPZ-Phen (3)). The mortality assay
demonstrates that the complex series had superior toxicity at all time-
points to cisplatin with the exception of Cu-DPPZ-Phen (3) which, in
comparison to Cu-Phen (1) and Cu-DPQ-Phen (2) was relatively non-
toxic. Previous studies have confirmed the enhanced toxicity of copper
complexes in comparison to platinum agents in G. mellonella larvae
[42].
Immune priming often plays a large role in the larval response to
foreign bodies, either chemical or pathological and alterations in the
larval haemocyte density is one of the earliest markers of the in-
vertebrate immune response [60]. Both controls and complex series
induced a non-significant increase in the haemocyte response after
complex exposure, which indicates that the novel Cu(II) complex series
does not elicit a generalised cellular immune response. The non-sti-
mulation of a non-specific immune response was also shown with the
Fig. 5. KEGG analysis of the metabolism of selected xenobiotics by cytochrome P450. Glutathione S-transferase (2.5.1.18) (pink) is shown to be significantly
upregulated in all test exposures.
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Fig. 6. KEGG analysis of significantly upregulated proteins in glycolysis/gluconeogenesis (highlighted: blue, green, grey, orange and pink) between all test exposures.
Cu-DPQ-Phen (2) shows no upregulation of 4.2.1.11 (phosphopyruvate hydratase) (pink).
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evaluation of the antimicrobial effects of 1,3-dibenzyl-4,5-diphenyl-
imidazol-2-ylidene silver(I) acetate (SBC3) in G. mellonella post infec-
tion with Staphylococcus aureus and Candida albicans [44]. In contrast,
other studies have shown a priming of the larval immune response with
biologically derived echinocandines producing a resistance to sub-
sequent infection [53]. The priming of the immune response has been
previously observed through amplification of immune related genes
[41, 54, 61]. This study in contrast shows significant decreases in IMPI
and transferrin gene expression after exposure to the metallo-agents
compared to the solvent control. Transferrin is typically increased fol-
lowing infection and based on functional homology with mammalian
systems, sequesters biologically active iron from circulation to prevent
it from being used as a microbial growth factor. IMPI was first identified
in G. mellonella and is responsible for breaking down metal based
proteases released by microbial pathogens [62]. Significantly, across
the complex series there is no increase in either of these antimicrobial
factors, indicating that at a cellular and messenger Ribonucleic Acid
(mRNA) level, the Cu(II) complexes are not eliciting a larval immune
response in a similar fashion to carbene silver(I) acetate (SBC3) ex-
posure [44]. In contrast, the larval exposure to caspofungin induces an
immune priming reaction [53].
In this study, LFQ proteomics produced a high-resolution analysis of
the larval response to the complex series with the possibility of gaining
an insight into the potential response in the mammalian system. Two-
dimensional poly acrylamide gel electrophoresis (2D-PAGE) provides a
lower resolution confirmation of several proteins detected in the LFQ
proteomics. Using 2D-PAGE proteomics the downregulation of three
proteins was confirmed in addition to 4 other detections of lower
abundance proteins (Supplementary Table V-VI). Both 2D-PAGE and
LFQ proteomics supports the finding of decreased immune response
found in the immune related gene expression and the non-significant
increase in the larval haemocyte response. 2D-PAGE analysis showed
that imaginal disc growth factor and apolipophorin was downregulated
in larvae treated with either Cu-DPQ-Phen (2) or Cu-DPPZ-Phen (3).
Additionally, transferrin, juvenile like binding hormone and 27 kDa
hemolymph protein was downregulated after exposure of larvae to Cu-
DPPZ-Phen (3). All larvae were exposed to the 24 h LD50 value of the 3
complexes but have a different number of proteins significantly altered
in abundance.
GST is a family of phase II detoxification enzymes that catalyses the
conjugation of glutathione to a wide variety of endogenous and exo-
genous electrophilic compounds by making the exogenous molecule
more hydrophilic, which aids in its elimination [63, 64]. Studies have
shown GST abundance to be elevated during oxidative stress in the
mammalian system [65]. Evidence has also linked the GST isozymes to
anti-cancer drug resistance [66]. The action of copper N-(2-hydroxy
acetophenone) glycinate has shown promise in overcoming doxorubicin
generated GST and Multi Drug Resistance (MDR) [67]. KEGG analysis
of the metabolism of xenobiotics by cytochrome P450 (Fig. 5) high-
lighted the involvement of GST in detoxification of benzo-[a]-pyrene
and napthalene both of which contain polycyclic aromatic rings which
are present in the phenazine ligand in Cu-DPQ-Phen (2) and Cu-DPPZ-
Phen (3). The upregulation of GST is also involved in the detoxification
of cyclophosphamide and ifosfamide which are key therapeutic alky-
lating agents. Cu-Phen (1), Cu-DPQ-Phen (2) and Cu-DPPZ-Phen (3)
have previously been shown to have nuclease cleaving ability [32], and
potentially interact with DNA through intercalation properties at the
minor groove as seen with the ruthenium complex Λ-[Ru
(phen)2dppz]2+ [68].
Cu-DPQ-Phen (2) and Cu-DPPZ-Phen (3) have previously been
shown to generate excellent Superoxide Dismutase (SOD) mimetic ac-
tivity with a progressive Fenton reaction matching the cadence of the
chemical nuclease capacity against pUC19 DNA [32]. Mitochondrial
aldehyde dehydrogenase and mitochondrial superoxide dismutase have
been shown to be closely associated with oxidative stress [69, 70]. The
upregulation of activity of these proteins in both the Cu-DPQ-Phen (2)
and Cu-DPPZ-Phen (3) treated larvae may be associated with increased
oxidative stress. Aldehyde dehydrogenase in mammalian cells has been
associated with tolerance to increased organic nitrates [71], which are
known to produce oxidative stress. The upregulation of both aldehyde
dehydrogenase and superoxide dismutase in the Cu-DPQ-Phen (2) and
Cu-DPPZ-Phen (3) treated larvae rather than just the upregulation of
aldehyde dehydrogenase in the Cu-Phen (1) may indicate that oxidative
stress plays a stronger mechanistic role in the secondary phenazine li-
gands despite the lower LD50 value. Isocitrate dehydrogenase is only
upregulated in Cu-Phen (1) exposure while malate dehydrogenase is
only upregulated in Cu-DPQ-Phen (2) and Cu-DPPZ-Phen (3) treated
larvae. These dehydrogenases are closely linked to the Tricarboxylic
Acid (TCA) cycle and have an effect on Nicotinamide Adenine Dinu-
cleotide +/H (NAD+/NADH) ratio, which has been the subject of re-
newed interest due to its capacity to alter/ameliorate the effects on
aging and other complex disease phenotypes [72]. An additional de-
hydrogenase present at increased levels of abundance in all exposures is
15-hydroxylprostaglandin dehydrogenase[NAD(+)] which has been
shown to suppress eicosanoids such as prostaglandins and liposin,
previously demonstrated to have anticancer properties [73].
KEGG analysis of glycolysis/gluconeogenesis (Fig. 6) indicated up-
regulation of fructose bisphosphate, triose phosphate isomerase, gly-
ceraldehydes-3-phosphate dehydrogenase and phosphopyruvate hy-
dratase (enolase) after exposure to all complexes. Previous studies have
shown enolase to become up regulated in response to cellular stress
[74]. Based on the study conducted by Molphy et al. [32], Cu(II) phe-
nanthroline-phenazine complexes showed chemical nuclease activity in
pUC19 plasmid DNA. Chemical nuclease action on larval DNA may
have contributed to cellular stress and related alterations in carbohy-
drate metabolism. Glyceraldehyde-3-phosphate dehydrogenase was
also highlighted and is involved in the conversion of glyceraldehydes-3-
phosphate to D-glycerate. The non-enzymatic elimination of phosphate
groups from glyceraldehyde-3-phosphate can lead to the production of
the cytotoxic methylglyoxal which is known to be a progenitor of ad-
vanced glycation end-products [75].
Purine metabolism from KEGG analysis (Fig. 7) indicated increased
abundance of regulatory enzymes SAICAR, AICAR and other purine
support enzymes. Changes in purine metabolism as a result of cellular
stress states have promoted increased interest recently as a potential
therapeutic target for new drug development [76]. Among some of the
new studies is evidence for the formation of a dynamic multi-enzyme
complex (purinosome) proximal to the mitochondria and microtubules
[77]. The formation of this multimeric protein complex has been as-
sociated with the depletion of purines and the upregulation of heat
shock 90 protein (HSP90) which aids in higher order protein structure
[76]. Based on the KEGG analysis, HSP90 was observed at higher levels
of abundance in larvae treated with all test complexes highlighting the
potential involvement of the newly described purinosome in the me-
chanistic response to nuclease active drugs due to accelerated DNA
breakdown from the cleavage activity of the metal complexes.
The GO analysis demonstrated marked elevation in the following
protein groups: cellular nitrogen compound metabolic process, orga-
nonitrogen compound metabolic process, heterocyclic metabolic pro-
cess, organic cyclic compound metabolic process, organic substance
biosynthetic process and small molecule metabolic process associated
proteins. The increased abundance of proteins associated with the
complex series and in particular, Cu-DPQ-Phen (2) and Cu-DPPZ-Phen
(3) are accompanied by a broad upregulation in detoxification and
degradation pathways. The increased abundance of nitrogen con-
taining, heterocyclic and small molecule related metabolism most likely
reflects the cellular detoxification response to the complexes which
peaks upon administration with Cu-DPQ-Phen (2) and Cu-DPPZ-Phen
(3). The GO analysis of molecular function at level 4 ontology showed
an elevated group of proteins indicative of DNA binding by all the test
complexes; nucleotide binding and nucleoside phosphate binding. The
upregulated activity of these groups of proteins may reflect an
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increased association with DNA damage and potential repair com-
plexes. Radical hydroxyl attack is believed to be an effect of these
complexes owing to their previously established Fenton chemistry [32].
5. Conclusion
This investigation showed that the extension of the phenazine π-
backbone within the complex scaffold resulted in a decrease in both
mortality and immune response in the larval model with the trend
following Cu-Phen < Cu-DPQ-Phen < Cu-DPPZ-Phen. Similarly to
previous studies, enhanced toxicity is observed with increased nuclease
capacity, however in contrast enhanced DNA binding and thermal
melting stability governed by the extended phenazine π-framework
results in a decrease in mortality here [16, 78].
The label free quantitation (LFQ) mass spectrometry method pro-
duced a high-resolution assessment of the proteomic changes occurring
in the larvae in response to test complexes allowing for gene ontology
(GO) analysis of both biological and molecular functions to be per-
formed. The results indicated a prominent metabolic and detoxification
response which may provide an opportunity to develop drug targeting
to this region but also to utilise the larval model to evaluate future
therapeutic and targeting improvements.
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